{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T16:03:33Z","timestamp":1786982613199,"version":"build-2736575974"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2022,2,28]],"date-time":"2022-02-28T00:00:00Z","timestamp":1646006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2022,2,28]],"date-time":"2022-02-28T00:00:00Z","timestamp":1646006400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Drug Metab Pharmacokinet"],"published-print":{"date-parts":[[2022,5]]},"DOI":"10.1007\/s13318-021-00745-6","type":"journal-article","created":{"date-parts":[[2022,2,28]],"date-time":"2022-02-28T06:03:13Z","timestamp":1646028193000},"page":"419-429","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Assessment of the Effects of Inhibition or Induction of CYP2C19 and CYP2C9 Enzymes, or Inhibition of OAT3, on the Pharmacokinetics of Abrocitinib and Its Metabolites in Healthy Individuals"],"prefix":"10.1007","volume":"47","clinical-trial-number":[{"clinical-trial-number":"nct03634345","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03637790","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03937258","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Xiaoxing","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin E.","family":"Dowty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann","family":"Wouters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Svitlana","family":"Tatulych","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carol A.","family":"Connell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vu H.","family":"Le","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sakambari","family":"Tripathy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa T.","family":"O\u2019Gorman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer A.","family":"Winton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hernan","family":"Valdez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bimal K.","family":"Malhotra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,2,28]]},"reference":[{"key":"745_CR1","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1021\/acs.jmedchem.7b01598","volume":"61","author":"ML Vazquez","year":"2018","unstructured":"Vazquez ML, Kaila N, Strohbach JW, Trzupek JD, Brown MF, Flanagan ME, et al. Identification of N-{cis-3-[Methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cyclobutyl}propane-1-sulfo namide (PF-04965842): a selective JAK1 clinical candidate for the treatment of autoimmune diseases. J Med Chem. 2018;61:1130\u201352. https:\/\/doi.org\/10.1021\/acs.jmedchem.7b01598.","journal-title":"J Med Chem"},{"key":"745_CR2","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/s0140-6736(20)30732-7","volume":"396","author":"EL Simpson","year":"2020","unstructured":"Simpson EL, Sinclair R, Forman S, Wollenberg A, Aschoff R, Cork M, et al. Efficacy and safety of abrocitinib in adults and adolescents with moderate-to-severe atopic dermatitis (JADE MONO-1): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial. Lancet. 2020;396:255\u201366. https:\/\/doi.org\/10.1016\/s0140-6736(20)30732-7.","journal-title":"Lancet"},{"key":"745_CR3","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1001\/jamadermatol.2020.1406","volume":"156","author":"JI Silverberg","year":"2020","unstructured":"Silverberg JI, Simpson EL, Thyssen JP, Gooderham M, Chan G, Feeney C, et al. Efficacy and safety of abrocitinib in patients with moderate-to-severe atopic dermatitis: a randomized clinical trial. JAMA Dermatol. 2020;156:863\u201373. https:\/\/doi.org\/10.1001\/jamadermatol.2020.1406.","journal-title":"JAMA Dermatol"},{"key":"745_CR4","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1001\/jamadermatol.2019.2855","volume":"155","author":"MJ Gooderham","year":"2019","unstructured":"Gooderham MJ, Forman SB, Bissonnette R, Beebe JS, Zhang W, Banfield C, et al. Efficacy and safety of oral janus kinase 1 inhibitor abrocitinib for patients with atopic dermatitis: a phase 2 randomized clinical trial. JAMA Dermatol. 2019;155:1371\u20139. https:\/\/doi.org\/10.1001\/jamadermatol.2019.2855.","journal-title":"JAMA Dermatol"},{"key":"745_CR5","doi-asserted-by":"publisher","first-page":"1776","DOI":"10.1111\/bcp.13612","volume":"84","author":"E Peeva","year":"2018","unstructured":"Peeva E, Hodge MR, Kieras E, Vazquez ML, Goteti K, Tarabar SG, et al. Evaluation of a Janus kinase 1 inhibitor, PF-04965842, in healthy subjects: a phase 1, randomized, placebo-controlled, dose-escalation study. Br J Clin Pharmacol. 2018;84:1776\u201388. https:\/\/doi.org\/10.1111\/bcp.13612.","journal-title":"Br J Clin Pharmacol"},{"key":"745_CR6","doi-asserted-by":"publisher","first-page":"S80","DOI":"10.1016\/j.dmpk.2020.04.191","volume":"35","author":"M Dowty","year":"2020","unstructured":"Dowty M, Yang X, Lin J, Bauman J, Doran A, Goosen T, et al. P190\u2014The effect of CYP2C9 and CYP2C19 genotype on the pharmacokinetics of PF 04965842, A JAK1 inhibitor in clinical development. Drug Metab Pharmacokinet. 2020;35:S80. https:\/\/doi.org\/10.1016\/j.dmpk.2020.04.191.","journal-title":"Drug Metab Pharmacokinet"},{"key":"745_CR7","unstructured":"Luvox (fluvoxamine maleate) tablets, for oral use. Prescribing information. ANI Pharmaceuticals, Inc. 2019."},{"key":"745_CR8","unstructured":"US Food and Drug Administration. Drug development and drug interactions: table of substrates, inhibitors and inducers. 2020. https:\/\/www.fda.gov\/drugs\/drug-interactions-labeling\/drug-development-and-drug-interactions-table-substrates-inhibitors-and-inducers. Accessed 30 Nov 2021."},{"key":"745_CR9","unstructured":"Diflucan (fluconazole tablets) (fluconazole for oral suspension). Prescribing information. Pfizer Inc. 2020."},{"key":"745_CR10","unstructured":"Rifadin (rifampin capsules USP) (rifampin for injection USP). Prescribing information. Sanofi Aventis Inc. 2020."},{"key":"745_CR11","unstructured":"Probenecid (probenecid tablet, film coated). Prescribing information. Mylan Pharmaceuticals Inc. 2006."},{"key":"745_CR12","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1002\/jcph.1858","volume":"61","author":"EQ Wang","year":"2021","unstructured":"Wang EQ, Le V, O\u2019Gorman M, Tripathy S, Dowty ME, Wang L, et al. Effects of hepatic impairment on the pharmacokinetics of abrocitinib and its metabolites. J Clin Pharmacol. 2021;61:1311\u201323. https:\/\/doi.org\/10.1002\/jcph.1858.","journal-title":"J Clin Pharmacol"},{"key":"745_CR13","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1021\/tx800432c","volume":"22","author":"L Leclercq","year":"2009","unstructured":"Leclercq L, Cuyckens F, Mannens GS, de Vries R, Timmerman P, Evans DC. Which human metabolites have we MIST? Retrospective analysis, practical aspects, and perspectives for metabolite identification and quantification in pharmaceutical development. Chem Res Toxicol. 2009;22:280\u201393. https:\/\/doi.org\/10.1021\/tx800432c.","journal-title":"Chem Res Toxicol"},{"key":"745_CR14","doi-asserted-by":"publisher","DOI":"10.1002\/prp2.537","volume":"7","author":"ME Dowty","year":"2019","unstructured":"Dowty ME, Lin TH, Jesson MI, Hegen M, Martin DA, Katkade V, et al. Janus kinase inhibitors for the treatment of rheumatoid arthritis demonstrate similar profiles of in vitro cytokine receptor inhibition. Pharmacol Res Perspect. 2019;7: e00537. https:\/\/doi.org\/10.1002\/prp2.537.","journal-title":"Pharmacol Res Perspect"},{"key":"745_CR15","unstructured":"Wojciechowski J, Malhotra BK, Wang X, Fostvedt L, Valdez H, Nicholas T. Population pharmacokinetic-pharmacodynamic modeling of platelet time courses after administration of abrocitinib. In: Presented at: 11th American Conference on Pharmacometrics; November 9\u201313, 2020; Virtual."},{"key":"745_CR16","unstructured":"Fostvedt L, Wojciechowski J, Malhotra BK, Wang X, Valdez H, Rojo R, et al. Zero-inflated beta regression exposure-response modeling of the eczema area and severity index for patients taking abrocitinib. In: Presented at: 11th American Conference on Pharmacometrics; November 9\u201313, 2020; Virtual."},{"key":"745_CR17","doi-asserted-by":"publisher","first-page":"S(AB151)","DOI":"10.1016\/j.jaad.2020.06.691","volume":"83","author":"X Wang","year":"2020","unstructured":"Wang X, Huh Y, Curto M, Chan G, Dowty ME, O\u2019Gorman M, et al. Assessment of cytochrome P450 3A inhibition and induction of abrocitinib: midazolam drug drug interaction (DDI) study and oral contraceptive DDI study. J Am Acad Dermatol. 2020;83:S(AB151). https:\/\/doi.org\/10.1016\/j.jaad.2020.06.691.","journal-title":"J Am Acad Dermatol"},{"key":"745_CR18","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1016\/S0009-9236(98)90104-7","volume":"63","author":"N Brynne","year":"1998","unstructured":"Brynne N, Dalen P, Alvan G, Bertilsson L, Gabrielsson J. Influence of CYP2D6 polymorphism on the pharmacokinetics and pharmacodynamic of tolterodine. Clin Pharmacol Ther. 1998;63:529\u201339. https:\/\/doi.org\/10.1016\/S0009-9236(98)90104-7.","journal-title":"Clin Pharmacol Ther"},{"key":"745_CR19","doi-asserted-by":"publisher","first-page":"1338","DOI":"10.1016\/j.clinthera.2007.07.022","volume":"29","author":"VR Adams","year":"2007","unstructured":"Adams VR, Leggas M. Sunitinib malate for the treatment of metastatic renal cell carcinoma and gastrointestinal stromal tumors. Clin Ther. 2007;29:1338\u201353. https:\/\/doi.org\/10.1016\/j.clinthera.2007.07.022.","journal-title":"Clin Ther"},{"key":"745_CR20","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1007\/s40262-015-0240-z","volume":"54","author":"F Namour","year":"2015","unstructured":"Namour F, Diderichsen PM, Cox E, Vayssiere B, Van der Aa A, Tasset C, et al. Pharmacokinetics and pharmacokinetic\/pharmacodynamic modeling of filgotinib (GLPG0634), a selective JAK1 inhibitor, in support of phase IIB dose selection. Clin Pharmacokinet. 2015;54:859\u201374. https:\/\/doi.org\/10.1007\/s40262-015-0240-z.","journal-title":"Clin Pharmacokinet"},{"key":"745_CR21","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1007\/s002130051171","volume":"147","author":"MG Scordo","year":"1999","unstructured":"Scordo MG, Spina E, Facciol\u00e0 G, Avenoso A, Johansson I, Dahl ML. Cytochrome P450 2D6 genotype and steady state plasma levels of risperidone and 9-hydroxyrisperidone. Psychopharmacology. 1999;147:300\u20135. https:\/\/doi.org\/10.1007\/s002130051171.","journal-title":"Psychopharmacology"},{"key":"745_CR22","unstructured":"W Drug Interactions Solutions, School of Pharmacy. DIDB\u2014The Drug Interaction Database. Seattle, WA: University of Washington. https:\/\/www.druginteractionsolutions.org\/solutions\/drug-interaction-database\/. Accessed 30 Nov 2021."}],"container-title":["European Journal of Drug Metabolism and Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13318-021-00745-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13318-021-00745-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13318-021-00745-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,29]],"date-time":"2022-04-29T01:22:05Z","timestamp":1651195325000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13318-021-00745-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,28]]},"references-count":22,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,5]]}},"alternative-id":["745"],"URL":"https:\/\/doi.org\/10.1007\/s13318-021-00745-6","relation":{},"ISSN":["0378-7966","2107-0180"],"issn-type":[{"value":"0378-7966","type":"print"},{"value":"2107-0180","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,28]]},"assertion":[{"value":"8 December 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 February 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"These trials were sponsored by Pfizer Inc.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"All authors are employees and stockholders of Pfizer Inc.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"Upon request, and subject to review, Pfizer will provide the data that support the findings of this study. Subject to certain criteria, conditions and exceptions, Pfizer may also provide access to the related individual de-identified participant data. See\u00a0\n                      \n                      \u00a0for more information.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"All authors contributed to the study conception and design. Material preparation, data collection, and analysis were performed by XW, MO, AW, JAW, and ST. Bioanalytical data preparation and interpretation were performed by VL and ST. VL performed all statistical analyses of pharmacokinetics data. AW and ST contributed to study safety. The first draft of the manuscript was written by XW; all authors critically reviewed the drafts and approved the final manuscript.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}},{"value":"This research was conducted in accordance with the Helsinki Declaration of 1964 and its later amendments. The final protocol, any amendments, and informed consent documentation were reviewed and approved by the Independent Ethics Committee at the investigational center participating in the study.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Written informed consent was obtained from all participants prior to enrollment.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}